Post-translational modification of protein by ubiquitin (Ub) alters the stability, subcellular location, or function of the target protein, thereby impacting numerous biological processes and directly contributing to myriad cellular defects or disease states, such as cancer. Tracking substrate ubiquitination by fluorescence provides opportunities for advanced reaction dynamics studies and for translational research including drug discovery. However, fluorescence-based techniques in ubiquitination studies remain underexplored at least partly because of challenges associated with Ub chain complexity and requirement for additional substrate modification. Here we describe a general strategy, FRET diubiquitination, to track substrate ubiquitination by fluorescence. This platform produces a uniform di-Ub product depending on specific interactions between a substrate and its cognate E3 Ub ligase. The diubiquitination creates proximity between the Ub-linked donor and acceptor fluorophores, respectively, enabling energy transfer to yield a distinct fluorescent signal. FRET diubiquitination relies on Ub–substrate fusion, which can be implemented using either one of the two validated strategies. Method 1 is the use of recombinant substrate–Ub fusion, applicable to all substrate peptides that can bind to E3. Method 2 is a chemoenzymatic ligation approach that employs synthetic chemistry to fuse Ub with a substrate peptide containing desired modification. Taken together, our new FRET-based diubiquitination system provides a timely technology of potential to advance both basic research and translation sciences.

Post-translational modification of protein by ubiquitin (Ub) alters the abundance, subcellular location, or function of the target protein in a profound fashion that impacts numerous biological processes and directly contributes to myriad cellular defects or disease states, such as cancer. Tracking substrate ubiquitination by fluorescence provides opportunities for advanced reaction dynamics studies and for translational research including drug discovery. However, fluorescence-based techniques in ubiquitination studies remain underexplored at least partly because of challenges associated with Ub chain complexity and requirement for additional substrate modification. Here we describe a general strategy, FRET diubiquitination, to track substrate ubiquitination by fluorescence. This platform produces a uniform di-Ub product depending on specific interactions between a substrate and its cognate E3 Ub ligase. The diubiquitination creates proximity between the Ub-linked donor and acceptor fluorophores, respectively, enabling energy transfer to yield a distinct fluorescent signal. FRET diubiquitination relies on Ub–substrate fusion, which can be implemented using either one of the two validated strategies. Method 1 is the use of recombinant substrate–Ub fusion, applicable to all substrate peptides that can bind to E3. Method 2 is a chemoenzymatic ligation approach that employs synthetic chemistry to fuse Ub with a substrate peptide containing desired modification. Taken together, our new FRET-based diubiquitination system provides a timely technology of potential to advance both basic research and translation sciences.

© 2021 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
addition, detection of fluorescent signal is often via indirect approaches, typically through antibody-aided methods (12–14). The indirect FRET techniques, however, may result in undesirable signal/background ratio. Finally, ubiquitination typically produces chains of heterogeneous size, and this complexity may compromise reproducibility. Thus, it is desirable to devise a strategy that yields a uniform Ub product to ensure a high degree of reproducibility critical to HTS success.

To address these challenges, we developed a novel “FRET diubiquitination” system that utilizes recombinant fusion or chemoenzymatic ligation strategy to generate a fusion between Ub and substrate. We demonstrate that such a fusion substrate is active, allowing measurement of E3-dependent diubiquitination by fluorescence in real time.

Results

Design FRET diubiquitination

To advance ubiquitination studies using fluorescent probes, we developed FRET diubiquitination system characterized by two main features (Fig. 1A). First, diubiquitination is based on an Ub–substrate fusion strategy. This fusion creates a dual-function molecule. On the one hand, it contains a substrate peptide capable of interacting with its cognate E3 ligase. Owing to the ability of an E3 to recruit an E2–donor Ub thiol ester (3), the fusion molecule can nucleate a complex of substrate–E3–E2–donor Ub. On the other hand, the substrate-linked Ub provides a receptor lysine residue to attack the E2–donor Ub thiol ester. In addition, the donor Ub is altered by site-directed mutagenesis to eliminate an internal lysine residue required for Ub chain assembly by the select E2. As a consequence, the Ub–substrate fusion molecule directs diubiquitination only, producing a uniform di-Ub product. The second feature of the FRET diubiquitination is the placement of a pair of distinct fluorophores into the donor and receptor Ub, respectively. The juxtaposition of two Ub-linked fluorophores, as a result of diubiquitination, results in energy transfer to yield a tractable fluorescent signal.

In this work, we used a well-characterized model ubiquitination system comprising substrate IkBa, Skp1–Cullin1–Fbox protein E3 ligase (E3 SCFβTrCP), and E2 cell division cycle 34 (Cdc34) (19). Figure 1B shows design of the Ub–IkBa fusion. Human IkBa N-terminal fragment (amino acids 1–54) was used, and it contains a signature 6-amino acid phosphodegron that is known to engage affinity interactions with E3 SCFβTrCP (21). To engineer a constitutively active IkBa degron, serine residues 32 and 36 were replaced by glutamic acid to mimic phosphorylation. In addition, IkBa K21 and K22, the authentic receptors for ubiquitination, were removed and replaced by Ub residues 1 to 74. The fusion product, IkBa (1–54)S32ES36E–Ub, is designated as IkBa (EE)–Ub. Previous studies have validated the function of IkBa (EE)–Ub, which allows ubiquitination by SCFβTrCP without the need of phosphorylation by IKKβ (20). In addition, multiple lines of evidence demonstrated the function of the fusion Ub as a receptor for ubiquitination (22).

For FRET, we placed a pair of distinct fluorophores into specific sites located within the donor and receptor Ub, respectively, as illustrated in Figure 1C. The donor Ub carries a cysteine substitution at position Q31, and the resulting Ub C31 is linked to fluorophore iFluor 555 through maleimide-mediated coupling. Likewise, the receptor Ub is modified to contain a change at position 64 (E → C), where fluorophore iFluor 647 is placed. As shown by our recent study (20), incubation of this pair of fluorescently labeled donor and receptor Ub molecules with E1, E2 Cdc34, and an E3 subcomplex (RING-box protein 1 [ROC1]–Cullin1 [CUL1] CTD) formed a di-Ub product that generated a distinct fluorescent signal. These findings have validated the design of the fluorophore placement.

FRET IkBa diubiquitination tracks ubiquitination in real time

FRET IkBa diubiquitination is a multistep reaction. IkBa (EE)–Ub (carrying fluorescent label iFluor 647) interacts with E3 SCFβTrCP to form the E3/substrate–Ub (I647) complex. The donor Ub (K48R, carrying fluorescent label iFluor 555), designated as Ub (K48R/I555), is activated by E1 to form E1–Ub (K48R/I555), which then reacts with E2 Cdc34 to yield Cdc34–Ub (K48R/I555). Upon mixing SCFβTrCP/IkBα (EE)–Ub (I647) and Cdc34–Ub (K48R/I555), lysine 48 (K48) from IkBa (EE)-linked receptor Ub (I647) attacks Cdc34–Ub (K48R/I555) to form the IkBa di-Ub product. As a consequence, Ub-linked fluorophores iFluor 555 and iFluor 647 are in close proximity optimal for energy transfer (FRET). E2 Cdc34 catalyzes K48 ubiquitination specifically (22). The use of donor Ub K48R allows only one nucleophilic attack, producing a single Ub–Ub isopeptide bond.

The reaction was first analyzed by standard gel electrophoresis followed by imaging fluorescent products with a scanner. As shown, the product IkBα–Ub2 increased with time (Fig. 2A, top), and >30% of the input donor Ub was converted into the product after 10 min of incubation. For FRET, a reaction aliquot was spotted onto a 384-well plate for spectroscopic analysis. FRET signal was detected, and its intensity increased with time in a manner coincidental with the abundance of IkBα–Ub2 detected by gel analysis (Fig. 2A, bottom). These results conclude that the observed FRET reflects the formation of IkBα–Ub2 as a result of enzymatic synthesis. The results of titration experiments showed that the FRET IkBα diubiquitination required E1 (Fig. 2B), E2 Cdc34 (Fig. 2C), and E3 SCFβTrCP (Fig. 2D).

To track the FRET IkBα diubiquitination in real time, SCFβTrCP/IkBα (EE)–Ub (I647) and Cdc34–Ub (K48R/I555), preassembled in separate tubes, were mixed in a 384-well plate followed by incubation at 30 °C on a fluorescence reader. Real-time fluorescence was recorded as the ubiquitination proceeded. The results revealed that FRET increased over 30 min (Fig. 3A). As shown by gel analysis, 85% of the input substrate–Ub was converted into the product after the reaction (Fig. 3B). Z’ factor measures statistical effect size based on the means and standard deviations of both the positive and negative control samples (23). Three independent experiments were
performed with both the complete experiment and the no E1 negative control, resulting in the determination of the $Z'$ factor $>0.5$, an indication of acceptable reproducibility (Fig. 3C). In addition, analyte titration experiments were carried out to assess the assay's sensitivity, that is, the lower limit of detection, which is commonly defined as the threshold analyte concentration when signal-to-noise ratio equals to 3. Based on the results of the titration experiments (Fig. 3D), the lower limit of detection of the assay was found to be 35 nM. Finally, E3 SCF$^{\beta}$TrCP is made of two functional subcomplexes: Skp1–$\beta$TrCP that targets substrates such as IkBa, and Nedd8–ROC1–CUL1 that functions to recruit E2 Cdc34–Ub for catalysis (19). To determine the dependency of the reaction on substrate targeting by E3, we performed an Nedd8–ROC1–CUL1 titration experiment in the presence or the absence of Skp1–$\beta$TrCP. The results revealed requirements for both

---

**Figure 1. FRET diubiquitination design.** A, general scheme. Diubiquitination is a result of mixing two reaction assemblies. On the right hand, a substrate–receptor Ub fusion, in which Ub is labeled with red-coded acceptor fluorophore, binds to its cognate E3 to form the E3/substrate–Ub complex (assembly 1). On the left hand, a donor Ub, containing a lysine substitution that eliminates Ub chain assembly, is labeled with green-coded donor fluorophore. This donor Ub reacts with E1 and E2 to form E2–donor Ub thiol ester complex (assembly 2). The combination of assemblies 1 and 2 produces a uniform substrate–diUb product, resulting in close proximity between the red and green fluorophores, respectively. When the donor fluorophore is excited, its emission causes the excitation of the acceptor fluorophore, which emits a distinct fluorescent signal. B, Ub fusion with IkBa phosphomimetic degron. IkBa (1–54) is a well-characterized N-terminal fragment of IkBa that contains all the molecular elements required for degradation (19). It possesses a phosphodegron (DpSGLDpS) that binds to E3 SCF$^{\beta}$TrCP. To mimic phosphorylation, S32 and S36 are replaced by glutamic acid (E). In addition, IkBa K21 and K22, the authentic receptors for ubiquitination, are replaced by Ub (1–74), which now provides K48 as the attacking lysine residue. This fusion is named IkBa (EE)–Ub. The N-terminal GST tag can be removed by thrombin cleavage. C, fluorophore placement on Ub. Donor Ub Q31 and receptor Ub E64 are substituted by cysteine and labeled with the indicated fluorescent dye. Ub, ubiquitin.
subcomplexes (Fig. 3E). Combining with the results of the E1/E2 Cdc34 titration experiments (Fig. 2, B–C), these findings established the specificity of the FRET IκBα diubiquitination assay.

**Characterization of the FRET IκBα diubiquitination**

We assessed whether the FRET IκBα diubiquitination maintains properties characteristic of ubiquitination. To this end, we performed the FRET IκBα diubiquitination under single-round turnover condition. For this purpose, SCFβTrCP/IκBα (EE)–Ub (I647) and Cdc34/C24 Ub (K48R/I555), preassembled in separate tubes, were each treated with apyrase to deplete ATP prior to mixing for ubiquitination. The effectiveness of ATP depletion by the apyrase protocol was validated previously (24). The results revealed that FRET plateaued at 30 min, utilizing about 20% of substrate input (Fig. 4), indicating that FRET IκBα diubiquitination indeed proceeds under the single-round turnover conditions.

We then assessed competitive inhibition of the FRET IκBα diubiquitination. Competition experiments were performed using nonfluorescent substrate IκBα (EE)–Ub (E64C) as competitive inhibitor. As shown, the nonfluorescent substrate, in amount 2.5 times in excess to the labeled substrate, almost completely blocked FRET (Fig. 5A). Gel analysis showed that excess nonfluorescent substrate inhibited consumption of the labeled input substrate (Fig. 5B, lanes 1–3). On the other hand, the nonfluorescent substrate was active, yielding IκBα–Ub2 as visualized by Coomassie stain (Fig. 5B, lanes 4–6). To confirm this effect, we have performed competition experiments with the phospho-β catenin degron peptide as a competitor. Previous crystallographic and biochemical studies have shown binding of the phospho-β catenin degron peptide to βTrCP (21) and ability of this peptide to support ubiquitination by SCFβTrCP (24). As shown, the phospho-β catenin degron peptide was able to effectively compete against the fluorescent IκBα substrate by blocking the FRET IκBα diubiquitination (Fig. 5C). In all, these results suggest that the use of fluorescence did not alter reaction properties.

---

**Figure 2. Detection of FRET IκBα diubiquitination.** A, FRET IκBα diubiquitination in test tube was carried out as described in Experimental procedures section. After incubation for times as indicated, aliquots of the reaction were subjected to analysis by gel electrophoresis (top) or spectroscopy (bottom). B–D, titration of E1 (B), E2 Cdc34 (C), and E3 SCFβTrCP (D).
Chemoenzymatic ligation and FRET β-catenin diubiquitination

The FRET IκBα diubiquitination requires the recombinant Ub fusion technique, which can apply to substrates that in the absence of modification can interact with E3, or that carry a phosphodegron but can be mimicked by amino acid substitutions, such as IκBα (EE) (Fig. 1B). However, the recombinant Ub fusion approach may not be applicable to many substrate degrons containing post-translational modifications that cannot be readily mimicked by amino acid substitutions. To address this issue and broaden the applicability of the FRET diubiquitination approach, we have developed an alternative strategy to generate Ub–substrate fusion (Fig. 6). In this approach, the β-catenin phosphodegron peptide (NH2-CAWQQSFDLP(S)GHIH(S)GATTTAP-OH) (Fig. 6A) was linked to Ub by chemoenzymatic ligation in vitro (Fig. 6B). The chemoenzymatic method is based on modification of a previously reported strategy that couples Cys–enhanced GFP to Ub by using both E1 enzyme catalysis and chemistry (25). We chose the β-catenin phosphodegron peptide (Fig. 6A) because it exhibits binding to βTrCP in a previously reported cocystallographic study (21), supports efficient in vitro ubiquitination by SCFβTrCP (24, 26), and acts as an effective competitor for the FRET IκBα diubiquitination (Fig. 5C). Note that the D(pS)GIH(pS) motif within this peptide (Fig. 6A), containing two phosphoserine residues incorporated chemically, is nearly identical to the degron in IκBα (Fig. 1B).

As schemed in Figure 6B, the chemoenzymatic ligation reaction is initiated by E1 that reacts with Ub to form an E1–S/C24 Ub thioester. Because E1 does not possess the basic residues necessary for deprotonating amine-based nucleophiles, the E1–S/C24Ub intermediate readily reacts with nucleophilic thiols, such as GSH, to form an Ub–S/C24–I647. Such Ub–S/C24–I647 then reacts with the synthetic Cys–β-catenin peptide, resulting in formation of Ub–Cys–β-catenin. Because Ub

**Figure 3.** Tracking FRET IκBα diubiquitination in real time. A, real-time kinetics. The real-time kinetic experiments were carried out as described in Experimental procedures section. The emission spectrum of 544 to 700 nm for the complete reaction and no E1 control are shown. B, gel analysis. The final reaction mixture was subjected to SDS-PAGE and Typhoon FLA9500 imaging analysis. C, assessing reliability. Three independent real-time kinetic experiments were carried out, and the results are plotted to reveal standard deviation and calculate Z factor. The ratio of 670/570 nm represents the FRET efficiency. Note that ifluo 647 (receptor fluorophore) emits at 670 nm, whereas ifluo 555 (donor fluorophore) emits at 570 nm. D, analyte titration. The analyte concentrations are as indicated. The concentrations of enzymes are as follows: E1 (50 nM), E2 Cdc34b (3 μM), and E3 Nedd8–SCFβTrCP (100 nM). S/N = (mean of signal – mean of background)/standard deviation of background. The reaction at 30 °C was monitored on the fluorescence plate reader for 30 min. The 15 min time point (in linear range of the reaction) is used for graph. E, dependency on Skp1–βTrCP and Nedd8–ROC1–CUL1. Skp1–βTrCP (100 nM), donor/receptor Ub (2.5 μM), E2 (50 nM), Cdc34b (1 μM), IκBα (EE)–Ub (E64C)–I647 (2.5 μM) and Ub (K48R/Q31C)–I555 (2.5 μM) were used. The concentrations of Nedd8–ROC1–UL1 are as indicated. The 30 min time point (in linear range of the reaction) is used for graph. Ub, ubiquitin.
Tracking substrate ubiquitination by fluorescence

Figure 4. Real-time kinetics of FRET IκBα diubiquitination under single-round turnover condition. The reaction was carried out as in Figure 3, A–C expect that the preformed substrate–E3 and donor Ub–E2 complexes were treated with apyrase (6 mU/1 μl) for 1 min at 37 °C to deplete ATP. The apyrase-treated reaction mixture was then loaded onto a 384-well plate for incubation on the Synergy-H1 reader set at 30 °C. The reaction was monitored at times as indicated. The emission spectrum of 544 to 700 nm for the complete reaction and no E1 control are shown. Ub, ubiquitin.

carries fluorophore iFluor 647 (Fig. 1C), Ub (I647)–β-catenin can be tracked by fluorescence imaging.

Incubation of the Cys–β-catenin degron peptide with Ub in the presence of E1 and GSH formed Ub–β-catenin with 37% efficiency (Fig. 7A, lane 5). Removal of E1 or GSH abolished the reaction (Fig. 7A, lanes 1 and 2). As shown, Ub–β-catenin was readily separated from unincorporated Ub and E1 by gel filtration (Fig. 7B). When the purified Ub–β-catenin was subjected to ubiquitination assay, nearly 70% of this fusion substrate was consumed, forming the Ub2–β-catenin product (Fig. 7C, lane 1). This reaction required intact SCBPTrCP (Fig. 7C, lanes 2 and 3).

To assess FRET β-catenin diubiquitination in real time, SCBPTrCP/Ub (I647)–β-catenin and Cdc34~Ub (K48R/I555), preassembled in separate tubes, were mixed in a 384-well plate followed by incubation at 30 °C on the fluorescence reader. Real-time fluorescence was recoded at every 5 min interval as the ubiquitination proceeded. The results revealed that FRET increased over 120 min (Fig. 8). As shown by gel analysis, ~30% of the input donor Ub was converted into the product after 120 min of incubation (Fig. 8, inset).

Discussion

Applicability of the FRET diubiquitination system

This work has established the FRET-based diubiquitination system. This platform produces a uniform di-Ub product depending on specific substrate–E3 interactions, such as those between E3 SCBPTrCP and IκBα or β-catenin phosphodegron (Fig. 1 and 6). The diubiquitination creates proximity between the Ub-linked donor and acceptor fluorophores, respectively, resulting in energy transfer to yield a distinct FRET signal (Figs. 2 and 8). In principle, a defined E3-binding segment from any substrate can be tested in the FRET diubiquitination system as long as its cognate E3 ligase, in purified form, can be obtained and can cooperate with a K48-specific E2 enzyme such as Cdc34. The FRET diubiquitination relies on Ub–substrate fusion, which can be implemented using either one of the two validated strategies. First is the use of recombinant Ub fusion. This method can apply to all substrate peptides that in their unmodified forms can bind to E3, or with modifications that can be mimicked by substituted amino acids, such as IκBα (EE)–Ub (Fig. 1B). The second strategy is chemoenzymatic ligation, which we have used to generate Ub–β-catenin (Fig. 6). While the recombinant Ub fusion method is cost effective with high yield, the chemoenzymatic ligation approach may be applicable for any substrate degron requiring a form of chemical modification that cannot be readily mimicked by amino acid substitutions.

There are limitations associated with the FRET diubiquitination system. First, the chemoenzymatic ligation method requires a degron of small size, preferably in the range of ~20 amino residues, such as the β-catenin degron peptide (Fig. 6A). This is because the E3–E2 complex anchored on the degron motif, such as the IκBα/β-catenin DpSGXXpS box, must be positioned near the K48 residue from the receptor Ub that is fused to the substrate degron. Such structural constrain limits the optimal spacing between the degron motif and the attacking lysine to be approximately 13 to 14 amino acid residues (21). Second, because the FRET fluorophore pair is chosen based on the K48 di-Ub structural model (Fig. 1C), the current diubiquitination assay most likely works with K48-specific E2s.
Figure 5. Real-time kinetics of FRET IkBα diubiquitination with competitor. A–C, except that nonfluorescent IkBα (EE)–Ub (E64C) was added 2.5× or 10× more than fluorescent IkBα (EE)–Ub (E64C)–I647. The reaction was analyzed by spectroscopic analysis (panel A), and gel electrophoresis followed by imaging (top) or Coomassie stain (bottom). The results showed that fluorescent IkBα–Ub2 product was decreased in the presence of the competitor (top, lanes 1–3). Coomassie staining revealed that nonfluorescent IkBα (EE)–Ub (E64C) was able to support ubiquitination, forming nonfluorescent IkBα–Ub2 (bottom, lanes 4–6). C, competition with β-catenin. The concentrations of enzymes and proteins are as follows: donor/receptor Ub (0.5 μM), E1 (50 nM), E2 Cdc34b (1 μM), Skp1–βTrCP (100 nM), Nedd8–ROC1–CUL1 (12 nM), IkBα (EE)–Ub (E64C)–I647 (0.5 μM), and Ub (K48R/Q31C)–I555 (0.5 μM). The reaction at 30 °C was monitored on the fluorescence plate reader for 30 min. The 18 min time point (in linear range of the reaction) is used for graph.
only, such as Cdc34. However, modifications can be made to accommodate diubiquitination of non-K48 linkage based on available structural models of Ub chains of various linkages (27).

**FRET diubiquitination measures ubiquitination in real time**

The FRET diubiquitination platform measures ubiquitination in real time under both multiple-round (Fig. 3) or single-round turnover (Fig. 4) conditions. Moreover, the reaction was

---

**Figure 6. Ligation of the β-catenin degron peptide to Ub.** A, the β-catenin degron peptide. The β-catenin degron peptide is shown. Phosphodegron motif, N-terminal Cys residue, and Flag-tag are indicated. B, ligation scheme. E1 and GSH were used to promote the ligation of the β-catenin degron peptide to Ub. Ub, ubiquitin.

**Figure 7. Preparation of Ub-β-catenin active in ubiquitination.** A, ligation reaction. The reaction was carried out as described in Experimental procedures section. Reaction products were imaged by Coomassie stain. The percentage of Ub converted to Ub-β-catenin is indicated. B, purification of β-catenin–Ub. Indicated fractions from chromatography through FPLC superdex-75 were separated by SDS-PAGE followed by imaging iFluor 647 using the Typhoon scanner. Ub-β-catenin and unincorporated Ub were well separated. C, Ub-β-catenin supports ubiquitination. The reaction was carried out as described in Experimental procedures section. Only in complete reaction (lane 1), Ub-β-catenin was conjugated with Ub-K0 to form Ub2-β-catenin.
susceptible to competitive inhibition (Fig. 5). These features may prove advantageous in studying ubiquitination dynamics concerning dynamic assembly and disassembly of complexes containing enzymes (E2/E3), Ub, and substrate. Currently, dynamics studies are limited because traditional methods typically monitor ubiquitination in test tubes by visualizing products resolved on denaturing polyacrylamide gels. In contrast, the FRET diubiquitination is robust and proceeds in a real-time format. Moreover, a fluorescence plate reader can be equipped with an automated dispenser that can dispense reagents to reactions at any desired time through injection with minimal disturbance. These features should allow the analysis of ubiquitination at levels of sensitivity and precision unmatched by conventional gel analysis.

FRET diubiquitination: a basis for HTS

The FRET diubiquitination platform uses a pair of matched fluorophores that are linked to the donor and receptor Ub, respectively, as illustrated in Figure 1C. Using this pair of probes, we have recently carried out an HTS and identified suramin that blocks the recruitment of E2 Cdc34 to the E3 ROC1–CUL1 subcomplex (20). Thus, it should be feasible to use the FRET diubiquitination reporter system as a platform for a powerful and activity-based HTS campaign to discover small-molecule inhibitors or activators that target substrate–E3 interaction. One attractive application of the FRET diubiquitination-based HTS would be to identify small-molecule antagonists that could block the ubiquitination of tumor suppressors and agonists that could stimulate the ubiquitination of oncoproteins. There is a growing list of tumor suppressors and oncogene products targeted by the Ub–proteasome system (28). As reviewed by Skaar et al. (5, 6), E3 SCF targets an array of oncogene products, such as β-catenin (by SCFβTrCP) and c-Myc (by SCFβTrCP), as well as tumor suppressors, such as p27 and p21 (by SCFSkp2). Studies with auxin-regulated SCFTIR1–Aux interactions (29) and lenalidomide mediated CRL4CRBN E3 Ub ligase activity (8-10) have provided proof-of-principle evidence for enhanced ubiquitination by small molecule probes.

Experimental procedures

Ub preparation

Yeast Ub in pET3a with an N-terminal tobacco etch virus cleavable His6-tag (pHisTEVUb) was used as the template plasmid. His–Ub–Q31C/K48R was constructed, expressed, purified, and labeled with iFluor 555 maleimide (AAT Bioquest) as described previously (20). Purified, labeled His–Ub–Q31C/K48R–I555 was used as a donor Ub throughout this study, unless indicated otherwise. His–Ub–E64C was similarly constructed, expressed, and purified. His–Ub–E64C was used for ligation with the β-catenin peptide degron in experiments shown in Figures 6–8.

Preparation of IxBa (EE)–Ub (E64C)–I647

The construction, expression, and purification of glutathione-S-transferase (GST)–IxBa (EE)–Ub (E64C) was
Tracking substrate ubiquitination by fluorescence

described previously (20) (used in Figs. 2–5). To prepare fluorescent IκBα (EE)–Ub (E64C)–I647, purified GST–IκBα (EE)–Ub (E64C) (20 mg) was treated with 10 mM tris(2-carboxyethyl)phosphine (TCEP) (Sigma) in degassed PBS for 15 min at room temperature, and then bound to Ni-nitrilotriacetic acid agarose beads (GE; 0.8 ml) for 1 h at 4 °C. After binding, the beads were washed with degassed PBS to remove TCEP and any unbound protein. For labeling, the beads were incubated with iFluor 647 maleimide (100 μM; AAT Bioquest; dissolved in N,N-dimethylformamide [Sigma]) and PBS in a final volume of 800 μl, with rotation, for 1 h at room temperature and then overnight at 4 °C, in the dark. Note that the aforementioned handling was performed inside an anerobic glove box (Captair Pyramid, Erlab) under nitrogen gas. The subsequent steps were performed in normal air. Following incubation, the beads were washed to remove unreacted dye, and then subjected to digestion by biotin–thrombin (10 U), with rotation, for 4 h at room temperature and then overnight at 4 °C. Supernatant was saved. The remaining beads were washed with buffer A (25 mM Tris–HCl, pH 7.5, 10% glycerol, 0.01% NP-40, and 1 mM DTT) plus 50 mM NaCl four times, 0.4 ml/time. The first two washes were saved and pooled with the supernatant, resulting in GST-free IκBα (EE)–Ub (E64C)–I647. This material was filtered to remove residual beads and dialyzed against 1 L of buffer A plus 50 mM NaCl.

The final IκBα (EE)–Ub (E64C)–I647 preparation was 0.7 mg/ml with a yield of 1.12 mg.

Ligation of the β-catenin degron peptide to Ub by chemoenzymatic reaction

Reaction mixture (10 μl) contained 50 mM Tris–HCl, pH 7.5, 5 mM MgCl₂, 2 mM ATP, 20 mM GSH (pH adjusted to 7.0), 0.5 μM His–E1, 12.5 μM His–Ub (E64C), and 75 μM β-catenin degron peptide (NH₂-CΑWQQQSYLD(pS)GIH(pS)GATTTPAP-OH; purchased from New England Peptide Inc) (Fig. 7A). The reaction was at 37 °C for 2 h. The reaction mixture was separated by 4 to 20% SDS-PAGE and visualized by Coomassie stain.

Preparation of Ub (E64C)–I647–β-catenin

Ligation of the β-catenin degron peptide to Ub (E64C), as described previously, was scaled up to 4.2 ml (used in Figs. 7C and 8). The entire reaction mixture was treated with 10 mM TCEP and then bound to Ni–nitrilotriacetic acid agarose (Qiagen; 0.1 ml) for 1 h at 4 °C. The beads captured His–Ub (E64C)–β-catenin, unconjugated His–Ub (E64C), and His–E1. After binding, the beads were washed with degassed PBS to remove TCEP and any unbound protein. The resulting beads were then incubated with iFluor 647 maleimide (10 μl in 500 μl of PBS), with rotation, for 1 h at room temperature and then overnight at 4 °C, in the dark. Note that the aforementioned handling was performed inside an anerobic glove box. The subsequent steps were performed in normal air. Following incubation, the beads were washed with PBS and then eluted with 250 mM imidazole in PBS (500 μl). The eluted material was filtered and dialyzed against 1 L of buffer A plus 50 mM NaCl.

To remove His–E1 and His–Ub (E64C)–I647, the aforementioned material was chromatographed through Superdex 75 (FPLC). The column was eluted with 500 ml of buffer A plus 150 mM NaCl. Fractions were collected and analyzed through gel electrophoresis followed by imaging iFluor 647 using the Typhoon FLA 9500 laser scanner (GE). As shown in Figure 7B, Ub (E64C)–I647–β-catenin and Ub (E64C)–I647 were well separated. Fractions containing Ub (E64C)–I647–β-catenin were pooled and used for ubiquitination experiments shown in Figures 7C and 8. The yield of Ub (E64C)–I647–β-catenin was 833 pmol (~10 μg) at 4.2 μM out of 56 nmol of His–Ub–E64C used.

Other reagents

The following reagents were prepared using established protocols. Skp1–βTrCP, ROC1–CUL1, PK–Ub, HA–Cdc34, and Ubc12 were prepared using methods described by Chong et al. (30). Nedd8–ROC1–CUL1 is a gift from N. Zheng of University of Washington, Seattle. Nedd8, Nedd8 E1, and human Ub–K0 were purchased from Boston Biochem.

Analysis of the FRET IκBα diubiquitination in test tube

Neddylation of ROC1–CUL1

The mixture contained 50 mM Tris–HCl, pH 7.4, 5 mM MgCl₂, 2 mM ATP, 0.5 mM DTT, 0.1 mg/ml bovine serum albumin, ROC1–CUL1 (0.45 μM), Nedd8 (20 μM), Nedd8 E1 (83 nM), and Ubc12 (15 μM) (Fig. 2). The reaction was incubated at room temperature for 10 min.

Assembly of the SCFβTrCP/IκBα (EE)–Ub (E64C)–I647 complex

Skp1–βTrCP (0.45 μM) was added to the aforementioned mix. Incubation continued at room temperature for 10 min. IκBα (EE)–Ub (E64C)–I647 (5 μM) was added, and the reaction volume was adjusted to 5 μl. The reaction was incubated for additional 10 min at room temperature.

Assembly of Cdc34–Ub (K48R/Q31C)–I555

The E2 charging reaction was assembled in a mixture (5 μl) that contained 50 mM Tris–HCl, pH 7.4, 5 mM MgCl₂, 2 mM ATP, 0.5 mM DTT, 0.1 mg/ml bovine serum albumin, Ub (K48R/Q31C)–I555 (6.6 μM), E1 (0.1 μM), and human Cdc34 (10 μM). The reaction was incubated for 5 min at 37 °C.

IκBα diubiquitination

The aforementioned mixture containing SCFβTrCP/IκBα (EE)–Ub (E64C)–I647 or Cdc34–Ub (K48R/Q31C)–I555 was mixed (a final volume of 10 μl). The reaction was incubated at 37 °C for times as indicated. For gel analysis, an aliquot of the products was separated by 4 to 20% SDS-PAGE and visualized by imaging using the Typhoon FLA 9500 laser scanner (GE). For spectroscopic analysis, an aliquot of the reaction mixture (1 μl) was mixed with 30 μl of PBS, and the mixture was
spotted onto a 384-well plate, which was read by the Synergy-H1 reader (BioTek).

**Real-time analysis of FRET IκBα diubiquitination**

For experiments shown in Figures 3, A–C, 4, and 5, A–B, SCFβTrCP/IκBα (EE)–Ub (E64C)–I647 complex and of Cdc34–Ub (K48R/Q31C)–I555 were each assembled in test tube as described in section “Analysis of FRET IκBα diubiquitination in test tube,” except that the reaction volume of 10 μl was used. These two mixes were combined in a well on a 384-well plate (Figs. 3–5). The incubation proceeded at 30 °C on the Synergy-H1 reader, and the reaction was monitored at times as indicated. The results are presented by either an emission spectrum of 544 to 700 nm (Figs. 3A, 4, and 5A) or a ratio of 670/570 nm (Figs. 3C and 5C) that represents the FRET efficiency.

For experiments shown in Figures 3, D and E and 5C, Ned68–ROCI–CUL1 was used, and hence, the neddylation reaction was omitted. The concentrations of enzymes and Ub are indicated in the legends to these figures. The results are presented by the ratio of 670/570 nm.

**Analysis of FRET β-catenin diubiquitination**

For the reaction shown in Figure 7C, it was carried out essentially the same way as described in “Analysis of FRET IκBα diubiquitination in test tube.” The exceptions are that Ub–I647–β-catenin (0.3 μM), neddylated SCFβTrCP (0.9 μM), Ub–K0 (20 μM), and Cdc34 (3 μM) were used. The reaction was at 37 °C for 30 min. The reaction mixture was separated by SDS-PAGE and visualized by imaging with the Typhoon scanner.

For the reaction shown in Figure 8, it was carried out essentially the same way as described in “Real time analysis of FRET IκBα diubiquitination.” The exceptions are that Ub–I647–β-catenin (0.3 μM), neddylated SCFβTrCP (0.9 μM), donor Ub (C31, K48R, and I555; 1 μM), and Cdc34 (3 μM) were used. The reaction, assembled on a 384-well plate, proceeded at 30 °C on the Synergy-H1 reader and was monitored at times as indicated. The ratio of 670/570 nm, representing the FRET efficiency, is presented.

**Data availability**

All data are contained within the article.

**Acknowledgments**—We thank J. Tseng for assistance in the chemoenzymatic ligation experiments and H. Miao and N. Zheng for reagents.

**Author contributions**—K. W., K. C., R. A. C., and Z.-Q. P. conducted the experiments; K. W., K. C., and Z.-Q. P. designed the experiments; K. W., K. C., R. A. C., and Z.-Q. P. performed key data analysis; and Z.-Q. P. wrote the article.

**Funding and additional information**—The following grants supported this work: National Institutes of Health (NIH) fellowship 1F30DK095572-01 to R. A. C. as well as NIH grants GM122751 and 1R01CA251425-01 to Z.- Q. P. Z.-Q. P. was also supported by Mount Sinai Technology and Development Fund Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: βTrCP, beta-transducin repeats-containing protein; Aux, auxin; Cdc34, cell division cycle 34; CRBN, cereblon; CRL4, Cullin-RING E3 ubiquitin ligase 4; CUL1, Cullin1; E1, E1 ubiquitin-activating enzyme; E2, E2 ubiquitin-conjugating enzyme; E3, E3 ubiquitin ligase; Fbxw7, F-box/WD repeat-containing protein 7; GST, glutathione-S-transferase; HTS, high-throughput screening; IκBα, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; Myc, myelocytomatosis; ROC1, RING-box protein 1; SCF, Skp1–Cullin1–Fbox protein 3 E3 ligase; Skp2, S phase kinase-associated protein 2; TCEP, tris(2-carboxyethyl)phosphine; TIR1, transport inhibitor response 1; Ub, ubiquitin.

**References**

1. Hershko, A., and Ciechanover, A. (1998) The ubiquitin system. *Annu. Rev. Biochem.* 67, 425–479
2. Rajalingam, K., and Dikic, I. (2016) SnapShot: expanding the ubiquitin code. *Cell* 164, 1074–1074.e1
3. Morreale, F. E., and Walden, H. (2016) Types of ubiquitin ligases. *Cell* 165, 248–248.e1
4. Baek, K., Krist, D. T., Prabu, J. R., Hill, S., Klügel, M., Neumaier, L. M., von Gronow, S., Kleger, G., and Schulman, B. A. (2020) NEDD8 nucleates a multivalent cullin-RING-UBE2D ubiquitin ligation assembly. *Nature* 578, 461–466
5. Skaar, J. R., Pagan, J. K., and Pagano, M. (2009a) SnapShot: F box proteins I. *Cell* 137, 1160–1160.e1
6. Skaar, J. R., D’Angiolella, V., Pagan, J. K., and Pagano, M. (2009) SnapShot: F box proteins II. *Cell* 137, 1358–1358.e1
7. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E. A. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. *Science* 303, 844–848
8. Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svininka, T., Heckl, D., Comer, E., Li, X., Ciarlo, C., Hartman, E., Munshi, N., Schenone, M., Schreiber, S. L., et al. (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. *Science* 343, 301–305
9. Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K. K., Bradner, J. E., and Kaelin, W. G., Jr. (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikars proteins. *Science* 343, 399–403
10. Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., Svininka, T., Schneider, R. K., McConkey, M., Járás, M., Griffiths, E., et al. (2016) Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. *Nature* 523, 183–188
11. Gururaja, T. L., Pray, T. R., Lowe, R., Dong, G., Huang, J., Daniel-Issakani, S., and Payan, D. G. (2005) A homogeneous FRET assay system for multiquatubiquitin chain assembly and disassembly. *Methods Enzymol.* 399, 663–682
12. Kerten, J. H., Davydov, I. V., Safiran, Y. J., Stewart, D. H., Oberoi, P., and Biebuyck, H. A. (2005) Assays for high-throughput screening of E2 AND E3 ubiquitin ligases. *Methods Enzymol.* 399, 682–701
13. Xu, S., Patel, P., Abbasian, M., Giegel, D., Xie, W., Mercurio, F., and Cox, S. (2005) In vitro SCF (beta-TrCP)-mediated I-kappa-B-alpha ubiquitination assay for high-throughput screen. *Methods Enzymol.* 399, 729–740

**Tracking substrate ubiquitination by fluorescence**

1R01CA251425-01 to Z. Q. P. Z. Q. P. was also supported by Mount Sinai Technology and Development Fund Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Tracking substrate ubiquitination by fluorescence

14. Huang, J., Sheung, J., Dong, G., Coquilla, C., Daniel-Issakani, S., and Payan, D. G. (2005) High-throughput screening for inhibitors of the E3 ubiquitin ligase APC. *Methods Enzymol.* **399**, 740–754

15. Madiraju, C., Welsh, K., Cuddy, M. P., Godoi, P. H., Pass, I., Ngo, T., Vasile, S., Sergienko, E. A., Diaz, P., Matsuzawa, S.-I., and Reed, J. C. (2012) TR-FRET-based high-throughput screening assay for identification of UBC13 inhibitors. *J. Biomol. Screen.* **17**, 163–176

16. Nakajima, H., Fujiwara, H., Furuichi, Y., Tanaka, K., and Shimbara, N. (2008) A novel small-molecule inhibitor of NF-kappaB signaling. *Biochem. Biophys. Res. Commun.* **368**, 1007–1013

17. Carlson, C. B., Horton, R. A., and Vogel, K. W. (2009) A toolbox approach to high-throughput TR-FRET-based SUMOylation and DeSUMOylation assays. *Assay Drug Dev. Technol.* **7**, 348–355

18. Ceccarelli, D. F., Tang, X., Pelletier, B., Orlicky, S., Xie, W., Plantevin, V., Neculai, D., Chou, Y. C., Ogunjimi, A., Al-Hakim, A., Varelas, X., Koszela, J., Wasney, G. A., Vedadi, M., Dhe-Paganon, S., et al. (2011) An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. *Cell* **145**, 1075–1087

19. Chong, R. A., Wu, K., Kovacev, I., and Pan, Z. Q. (2015) Generation of a proteolytic signal: E3/E2-mediated polyubiquitination of IκBα. *Methods Mol. Biol.* **1280**, 339–354

20. Wu, K., Chong, R. A., Yu, Q., Bai, J., Spratt, D. E., Ching, K., Lee, C., Miao, H., Tappin, I., Jerard Hurwitz, J., Zheng, N., Shaw, G. S., Sun, Y., Felsenfeld, D. P., Sanchez, R., et al. (2016) Suramin inhibits cullin-RING E3 ubiquitin ligases. *Proc. Natl. Acad. Sci. U. S. A.* **113**, E2011–E2018

21. Wu, G., Xu, G., Schulman, B. A., Jeffrey, P. D., Harper, J. W., and Pavletich, N. P. (2003) Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. *Mol. Cell* **11**, 1445–1456

22. Wu, K., Kovacev, I., and Pan, Z. Q. (2010) Priming and extending: an UbcH5/Cdc34 E2 handoff mechanism for polyubiquitination on a SCF substrate. *Mol. Cell* **37**, 784–796

23. Zhang, J.-H., Chung, T. D. Y., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomol. Screen.* **4**, 67–73

24. Kovacev, I., Wu, K., Spratt, D. E., Chong, R. A., Lee, C., Nayak, J., Shaw, G. S., and Pan, Z. Q. (2014) A snapshot at ubiquitin chain elongation: lysine 48-tetra-ubiquitin slows down ubiquitination. *J. Biol. Chem.* **289**, 7068–7081

25. Burchak, O. N., Jaquinod, M., Cottin, C., Mugherli, L., Iwai, K., Chatelain, F., and Balakirev, M. Y. (2006) Chemoenzymatic ubiquitination of artificial substrates. *Chembiochem* **7**, 1667–1669

26. Saha, A., and Deshaies, R. J. (2008) Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. *Mol. Cell* **32**, 21–31

27. Akutsu, M., Dikic, I., and Bremm, A. (2016) Ubiquitin chain diversity at a glance. *J. Cell Sci.* **129**, 875–880

28. Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., and Brownell, J. E. (2011) Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. *Nat. Rev. Drug Discov.* **10**, 29–46

29. Tan, X., Calderon-Villalobos, L. I., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., and Zheng, N. (2007) Mechanism of auxin perception by the TIR1 ubiquitin ligase. *Nature* **446**, 640–645

30. Chong, R. A., Wu, K., Spratt, D. E., Yang, Y., Lee, L., Nayak, J., Xu, M., Elkholi, R., Tappin, I., Li, J., Hurwitz, J., Brown, B. D., Chipuk, J. E., Chen, Z., Sanchez, R., et al. (2014) Pivotal role for the ubiquitin Y59-E51 loop in lysine 48 polyubiquitination. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 8434–8439